Last update Sept. 19, 2016

ビランテロールトリフェナテート

Compatible

Safe substance and/or breastfeeding is the best option.

Long-acting bronchodilator with a similar action than Salmeterol.

At latest update no published data on excretion into breast milk were found.

Plasma concentration after having inhaled bronchodilators is very low, so that a significant amount in the breast milk is not expected (Ellsworth 1994, McDonald 1996).
Its low oral bioavailability hinders the passage from ingested milk towards the infant’s plasma, except in preterm babies and immediate neonatal period, which may show an increased intestinal permeability.

Terbutaline, a molecule of the same family, is excreted in insignificant amounts in breast milk (Lindberg 1984).

Inhaled bronchodilators are preferred because of their lower doses (less risk of excretion into milk).

Alternatives

We do not have alternatives for ビランテロールトリフェナテート since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

ビランテロールトリフェナテート is Vilanterol Trifenatate in Japanese.

Is written in other languages:

Group

ビランテロールトリフェナテート belongs to this group or family:

Tradenames

Main tradenames from several countries containing ビランテロールトリフェナテート in its composition:

  • Breo Ellipta™. Contains other elements than ビランテロールトリフェナテート in its composition
  • Relvar Ellipta™. Contains other elements than ビランテロールトリフェナテート in its composition
  • Revinty™. Contains other elements than ビランテロールトリフェナテート in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 27 %
Molecular weight 775 daltons
T½ 1.5 - 2 hours

References

  1. Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, Johnson B, Albrechtsen C, Edenborough F, Rigau D, Gibson PG, Backer V. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020 Feb 6;55(2). pii: 1901208. Abstract Full text (link to original source) Full text (in our servers)
  2. Kelleher DL, Mehta RS, Jean-Francois BM, Preece AF, Blowers J, Crater GD, Thomas P. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012 Abstract
  3. Nelson-Piercy C. Asthma in pregnancy. Thorax. 2001 Abstract Full text (link to original source) Full text (in our servers)
  4. Ellsworth A. Pharmacotherapy of asthma while breastfeeding. J Hum Lact. 1994 Abstract

Total visits

1,745

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM